



ARTICLE

Monitoring Cellular Immune Responses after Consumption of Selected Probiotics in Immunocompromised Mice

Seok-Jin Kang^{1,2,†}, Jun Yang^{1,†}, Na-Young Lee¹, Chang-Hee Lee^{1,2}, In-Byung Park^{1,2}, Si-Won Park¹, Hyeon Jeong Lee¹, Hae-Won Park¹, Hyun Sun Yun³, and Taehoon Chun^{1,†,*}

¹Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea

²Institute of Animal Molecular Biotechnology, Korea University, Seoul 02841, Korea

³CJ CheilJedang Corporation, Suwon 16495, Korea

OPEN ACCESS

Received June 23, 2022

Revised August 2, 2022

Accepted August 11, 2022

*Corresponding author : Taehoon Chun
Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea
Tel: +82-2-3290-3069
E-mail: tchun@korea.ac.kr

*ORCID

Seok-Jin Kang
<https://orcid.org/0000-0002-9701-8690>
Jun Yang
<https://orcid.org/0000-0002-9260-7875>
Na-Young Lee
<https://orcid.org/0000-0001-6053-3528>
Chang-Hee Lee
<https://orcid.org/0000-0002-4424-7203>
In-Byung Park
<https://orcid.org/0000-0002-8646-8709>
Si-Won Park
<https://orcid.org/0000-0002-1597-9683>
Hyeon Jeong Lee
<https://orcid.org/0000-0003-0277-7377>
Hae-Won Park
<https://orcid.org/0000-0001-5915-2154>
Hyun Sun Yun
<https://orcid.org/0000-0002-4655-9462>
Taehoon Chun
<https://orcid.org/0000-0002-5940-8620>

† These authors contributed equally to this work.

Abstract Probiotics are currently considered as one of tools to modulate immune responses under specific clinical conditions. The purpose of this study was to evaluate whether oral administration of three different probiotics (*Lactiplantibacillus plantarum* CJLP243, CJW55-10, and CJLP475) could evoke a cell-mediated immunity in immunodeficient mice. Before conducting *in vivo* experiments, we examined the *in vitro* potency of these probiotics for macrophage activation. After co-culture with these probiotics, bone marrow derived macrophages (BMDMs) produced significant amounts of proinflammatory cytokines including interleukin-6 (IL-6), IL-12, and tumor necrosis factor- α (TNF- α). Levels of inducible nitric oxide synthase (*inos*) and co-stimulatory molecules (CD80 and CD86) were also upregulated in BMDMs after treatment with some of these probiotics. To establish an immunocompromised animal model, we intraperitoneally injected mice with cyclophosphamide on day 0 and again on day 2. Starting day 3, we orally administered probiotics every day for the last 15 d. After sacrificing experimental mice on day 18, splenocytes were isolated and co-cultured with these probiotics for 3 d to measure levels of several cytokines and immune cell proliferation. Results clearly indicated that the consumption of all three probiotic strains promoted secretion of interferon- γ (IFN- γ), IL-1 β , IL-6, IL-12, and TNF- α . NK cell cytotoxicity and proliferation of immune cells were also increased. Taken together, our data strongly suggest that consumption of some probiotics might induce cell-mediated immune responses in immunocompromised mice.

Keywords animal model, immune response, probiotics

Introduction

Immunosuppression is an abnormal physiological condition with temporary or long-lasting immune defects that might increase susceptibility to certain infectious diseases (Geha et al., 2007). Many anti-microbial drugs have been developed and tested for

treating immunocompromised person after infection. However, prolonged use of anti-microbial drugs often leads to several adverse effects such as allergic reaction, diarrhea, dysbiosis, and drug-induced liver injury (Mohsen et al., 2020). Therefore, the development of a more effective and safer method is required to treat such immunosuppressive diseases.

Probiotics are heterogenous microorganisms that give health benefits when they are consumed or applied to the host (de Melo Pereira et al., 2018). A recent study has provided evidence that consumption of some probiotics might be an effective therapeutic tool to increase overall immune responses of an immunosuppressed host (Gramajo Lopez et al., 2021). *L. plantarum* CJLP243 was originally derived from Kimchi, a traditional Korean food. It has been developed as food supplement to enhance helper T1 (Th1) activity (Lee et al., 2011; Won et al., 2011). Consumption of CJLP243 can alleviate the symptom of Th2 prone diseases such as birch pollen-induced allergic rhinitis by rebalancing Th1/Th2 responses and increasing cellular immunity (Choi et al., 2018).

In this study, consumption of three different probiotics of *L. plantarum* including CJLP243, CJW55-10, and CJLP475 were tested for their ability to induce cellular immunity in a cyclophosphamide (CPP)-induced immunosuppressive mouse model. As a result, the consumption of these probiotics promoted interferon- γ (IFN- γ), interleukin-1 β (IL-1 β), IL-6, and tumor necrosis factor- α (TNF- α) production, increased NK cell activity, and facilitated immune cell proliferation in immunodeficient mice. Our data suggested that consumption of selected probiotics can be developed as a food additive to induce cellular immunity.

Materials and Methods

Probiotics and animals

Isolation of *L. plantarum* CJLP243 was described previously (Lee et al., 2011). CJW55-10 was isolated from kimch and CJLP475 was isolated from fermented soybean paste according to a previously established method (Lee et al., 2011). Each probiotics was sub-cultured more than three times prior to *in vitro* experimental analysis.

C57BL/6 mice (female, 6–8 weeks old) were purchased from Orient Bio (Seongnam, Korea) and acclimated for one week prior to experiments. Mice were fed a standard rodent diet with purified water *ad libitum* and kept at 20°C–24°C with 40%–60% humidity in Korea University animal facility under a 12 h/12 h light-dark cycle. Mice received proper care in accordance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of Korea University (protocol number: KUIACUC-2020-0052).

Differentiation of bone marrow derived macrophages (BMDMs)

BM cells were isolated from femurs and tibias of mice and resuspended to 1×10^6 cells/mL in 30% L929-conditioned DMEM medium supplemented with 20% (v/v) FBS, 5×10^{-5} M β -mercaptoethanol, 20 mM HEPES, 1 mM sodium pyruvate, and 1% penicillin/streptomycin (Weischenfeldt and Porse, 2008). Culture medium was replenished four days after culture. On day 7, cells were harvested and the degree of BMDM differentiation was measured by flow cytometry analyses after staining with PE conjugated anti-mouse F4/80 (BioLegend, San Diego, CA, USA, cat. #123110) and antigen presenting cells (APC) conjugated anti-CD11b (BioLegend, cat. #101212) antibodies. More than 90% of cells displayed F4/80⁺CD11b⁺ phenotype.

Analysis of probiotics-stimulated bone marrow derived macrophages (BMDMs) *in vitro*

BMDMs (5×10^4 cell/well) were seeded into a 96-well plate in 200 μ L of RPMI-10 [RPMI medium supplemented with 10%

(v/v) FBS and 1% penicillin/streptomycin]. Each probiotics (6×10^6 CFU/mL) was co-cultured with BMDMs in a humidified 5% CO₂ atmosphere at 37°C for 3 d. As a positive control, lipopolysaccharide (LPS) (10 µg/mL) (Merck, Darmstadt, Germany) was used to treat BMDMs without incubation with each probiotics. As a negative control, vehicle (phosphate buffered saline, PBS) was also used to treat BMDMs. After co-culture, IFN-β (R&D Systems, Minneapolis, MN, USA, cat. #42400-1), IL-1β (Thermo Fisher Scientific, Waltham, MA, USA, cat. #BMS6002), IL-6 (Thermo Fisher Scientific, cat. #BMS603-2), IL-12 (Thermo Fisher Scientific, cat. #BMS616), and TNF-α (Thermo Fisher Scientific, cat. #BMS607-3) secretions from BMDMs were quantified by sandwich ELISA kits according to the manufacturer's instructions.

To quantify mRNA transcript of inducible nitric oxide synthase (*inos*), total RNA was extracted from BMDMs using Trizol reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. It was then reverse transcribed into cDNA using a First-Strand cDNA Synthesis kit with random hexamer and SuperScript RT (Thermo Fisher Scientific). After cDNA synthesis, quantitative real-time PCR was conducted on a Bio-Rad CFX96 Real-Time Detection System (Bio-Rad, Hercules, CA, USA) using QGreen™ 2X qPCR Master Mix (GenDEPOT, Katy, TX, USA). Relative expression levels of *inos* mRNA transcripts were normalized to mouse *Gapdh* level. Primer sequences for mouse *inos* were 5'-CCAGTTGTGCATCGACCT-3' (sense) and 5'-ATGCTCCATGGTCACCTC-3' (anti-sense), resulting in a 139 bp product. Primer sequences for mouse *gapdh* were 5'-ATGGTGAAGGTCGGTGTGAA-3' (sense) and 5'-GGTCGTTGATGGCAACAATCTC-3' (anti-sense), resulting in a 100 bp product.

Flow cytometry analyses were performed to determine surface expression of mouse MHC class II (A^b), CD80, and CD86 on BMDMs before stimulation and at 3 d after stimulation with each probiotics. For surface staining, FITC-conjugated anti-A^b antibody (Biolegend, San Diego, CA, USA, rat IgG_{2b}, cat. #107605), PE conjugated anti-mouse CD80 antibody (BD Biosciences, San Jose, CA, USA, hamster IgG, cat. #553769), and PE conjugated anti-mouse CD86 antibody (BD Biosciences, rat IgG_{2a}, cat. #553692) were used. FITC conjugated rat IgG_{2b} antibody (BD Biosciences, cat. #553988), PE conjugated hamster IgG₂ antibody (BioLegend, cat. #400908), and PE conjugated rat IgG_{2a} antibody (Thermo Fisher Scientific, cat. #12-4321-81) were used as isotype controls. After staining, BMDMs were analyzed by flow cytometry using a FACSVerser with FACSsuite software (BD Biosciences).

***In vivo* analysis using an immunocompromised animal model**

To confirm whether CPP treatment causes an immunodeficiency in mice, six of C57BL/6 mice were randomly divided into two groups (n=3 per group). One group of mice was received vehicle (PBS) and the other group of mice was intraperitoneally injected with CPP (150 mg/kg of body weight) in 200 µL of sterile PBS on day 0 and again on day 2. Three days after the first administration of CPP, all mice were sacrificed for monitoring immune cell populations using flow cytometry analyses. For monitoring thymocytes and T cell populations, FITC-conjugated anti-mouse CD3ε antibody (Biolegend, cat. #100714), PerCP-Cy5.5-conjugated anti-mouse CD4 antibody (BD Biosciences, cat. #550954) and APC-Cy7-conjugated anti-mouse CD8 antibody (Biolegend, cat. #100714) were used. For monitoring splenic B cells and NK cells, PE-conjugated anti-mouse B220 antibody (Biolegend, cat. #103208) and APC-conjugated anti-NK1.1 antibody (Invitrogen, Carlsbad, CA, USA, cat. #17-5941-81) were used.

After confirming the immunosuppressive effect of CPP treatment in mice, thirty of C57BL/6 mice were randomly divided into five groups (n=6 per group). One group of mice was received neither CPP nor probiotics and the rest four groups of mice were intraperitoneally injected with CPP (150 mg/kg of body weight) in 200 µL of sterile PBS on day 0 and again on day 2 to establish an immunocompromised animal model. On day 3, each mouse of the three CPP-treated groups started to receive

200 μL of PBS containing each probiotics (CJLP243, CJW55-10 or CJLP475) (1×10^{10} CFU per mouse) using a gavage needle every day for 14 consecutive days. The other CPP-treated group of mice started to receive 200 μL of vehicle (PBS) without probiotics starting from day 3 until day 17 as a negative control. On day 18, all mice were sacrificed for analyses (Choi et al., 2018).

After sacrificing mice, splenocytes from each animal were isolated and seeded into a 96-well plate at 1×10^6 cells/well in 200 μL of RPMI-10. Each probiotics (6×10^6 CFU/mL) was then co-cultured with splenocytes in a humidified 5% CO_2 atmosphere at 37°C . As a positive control, LPS (10 $\mu\text{g}/\text{mL}$) was used to treat splenocytes without incubation with each probiotics. Three days after incubation, IFN- γ (Thermo Fisher Scientific, cat. #BMS606-2), IL-1 β (Thermo Fisher Scientific, cat. #BMS6002), IL-6 (Thermo Fisher Scientific, cat. #BMS603-2), IL-12 (Thermo Fisher Scientific, cat. #BMS616), and TNF- α (Thermo Fisher Scientific, cat. #BMS607-3) secretions from splenocytes were quantified using sandwich ELISA kits according to the manufacturer's instructions.

To measure immune cell proliferation after challenging with probiotics, splenocytes were incubated with 5 μM of carboxyfluorescein succinimidyl ester (CFSE) at 37°C for 10 min, washed with RPMI-10, and then cultured with each probiotics or LPS. Three days after culture, the proliferation of CFSE-labeled cells was measured by flow cytometry.

To measure NK cell activity from probiotics-treated splenocytes, splenic NK cells were used as effector cells and YAC-1 cells (ATCC, Manassas, VA, USA) were used as target cells. Briefly, splenocytes (1×10^6 cell/well) from sacrificed mice and YAC-1 cells (1×10^4 cell/well) were seeded to 96-well plates in 200 μL of RPMI-10 and co-incubated at 37°C for 6 h. The cytotoxicity of target cells (YAC-1 cells) was then measured with an LDH assay kit (Takara Bio, Shiga, Japan) according to the manufacturer's instructions.

Statistical analysis

Student's t-test was used to analyze independent variables with mean values. Significant differences were measured with p-values and marked with asterisks (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

Results and Discussion

Macrophage activation by selected probiotics *in vitro*

Professional antigen presenting cells (pAPCs) play a pivotal role in initiating immune responses. Accordingly, macrophages not only stimulate innate immunity by secreting several cytokines, but also initiate adaptive immunity by providing an activation signal to naïve T cells to become effector T cells (Kambayashi and Laufer, 2014). To test whether selected probiotics including CJLP243, CJW55-10, and CJLP475 could be able to induce macrophage activation, BMDMs were co-cultured with these probiotics. After co-culture, we measured macrophage activity was measured with three parameters. First, *iNOS* expression levels were measured by quantitative real-time RT-PCR. The *iNOS* has been shown to play a critical role in activating macrophage function. Its level is augmented after exposure to proinflammatory cytokines such as IL-1 β and TNF- α (Ulisse et al., 2001). As expected, LPS-treated BMDMs significantly increased the mRNA level of *inos* compared to that of vehicle-treated BMDMs (Fig. 1A). Selected probiotics-treated BMDMs also increased mRNA levels of *inos* by more than 20 folds compared to vehicle-treated BMDMs (Fig. 1A). Especially, CJLP475-treated BMDMs displayed the highest fold increase of *inos* compared to vehicle-treated BMDMs (Fig. 1A).

Recently, immune modulatory role of probiotics is largely divided into two categories depending on a function of certain




Fig. 1. BMDMs stimulated with selected probiotics induce *inos* expression and pro-inflammatory cytokine production. BMDMs (5×10^4 cell/well) from C57BL/6 mice were co-cultured with each heat-killed probiotics (CJW55-10, CJLP243, or CJLP475) at a density of 6×10^6 CFU/mL. (A) Three days after co-culture, quantitative real-time RT-PCRs were performed to determine relative expression levels of *inos* in BMDMs. (B, C) After 3 d, quantities of pro-inflammatory cytokines (B) and IFN- β (C) in culture supernatants were determined by ELISAs. Vehicle, PBS treatment; LPS, LPS ($10 \mu\text{g/mL}$) treatment. All results are shown as means \pm SEM. Significant differences compared with the vehicle group are indicated as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. BMDM, bone marrow derived macrophage; *inos*, inducible nitric oxide synthase; IFN, interferon; PBS, phosphate buffered saline; LPS, lipopolysaccharide.

strain: Enhancing inflammatory responses or inhibiting inflammatory responses (Bui et al., 2015; Vincenzi et al., 2021). To determine immune modulatory effects of these probiotics, we measured levels of pro-inflammatory cytokines including IL-1 β , IL-6, IL-12, and TNF- α . As a positive control, we measured levels of these cytokines from LPS-stimulated BMDMs. As a result, LPS-treated BMDMs secreted enormous amounts of these cytokines compared to vehicle-treated BMDMs (Figs. 1B and C). Compared to vehicle-treated group, IL-6, IL-12, and TNF- α were produced significantly from these probiotics-treated BMDMs (Fig. 1B). However, BMDMs stimulated by these probiotics did not produce IL-1 β (Fig. 1B).

Notably, IL-12 is an essential cytokine to initiate Th1 immune response. It is currently developed as a potential immunological tool to destroy certain cancer (Nguyen et al., 2020). Similar to our results, previous observations have also indicated that certain probiotics strains can induce IL-12 production by macrophages (Shida et al., 2006). In addition, previous observations have demonstrated that probiotics can enhance anti-microbial responses by inducing type I IFNs (Gutierrez-Merino et al., 2020). Therefore, we also measured the production of IFN- β by BMDMs after stimulation with these probiotics. However, these probiotics did not stimulate macrophages to produce type I IFN (Fig. 1C).

Two signals are required for stimulation of Naïve T cells to turn into effector T cells. The interaction between peptide

antigen with MHC molecules on pAPCs and T cell receptor on naïve T cells delivers the first signal. The second signal is mediated by the interaction between CD80 or CD86 on pAPCs and CD28 on naïve T cells (Kambayashi and Laufer, 2014). Therefore, we measured expression levels of MHC class II (A^b) and co-stimulatory molecules (CD80 and CD86) to determine whether cell surface expression levels of these molecules were up-regulated on macrophages after stimulation with these probiotics. LPS-stimulated macrophages displayed increased expression levels of all three molecules (A^b , CD80, and CD86) (Fig. 2). Treatment with none of these probiotics led to increase expression of A^b on macrophages (Fig. 2A). However, the surface expression of either CD80 or CD86 was increased statistically when macrophages were treated with these probiotics (Figs. 2B and C). Combined evidence strongly suggest that macrophages stimulated with these probiotics can enhance immunity by increasing the production of *i*NOS, proinflammatory cytokines, and co-stimulatory molecules.

Consumption of selected probiotics induces cellular immune responses in immunodeficient mice

Since we found a stimulatory effect of these probiotics on macrophages *in vitro*, we further determined whether these probiotics could induce cell-mediated immunities in immunodeficient mice (Jimenez-Valera et al., 2003). CPP-treated mice are widely used in an immunocompromised animal model to test immunostimulatory role of several biological reagents. Treatment with CPP causes both myelopenia and leukopenia with reduced number of splenocytes within 5 d (Jimenez-Valera et al., 2003). To confirm the immunosuppressive effect of CPP in mice, we injected CPP (150 mg/kg) to mice twice with an interval of two days. Three days after the first administration of CPP, all mice were sacrificed and analyzed the changes of immune cell populations in thymus and spleen. As shown in Table 1, the numbers of thymocytes and T cells in thymus was severely reduced in CPP-treated mice compared to vehicle-treated mice. Also, the numbers of B cells and NK cells in spleen were significantly decreased in CPP-treated mice compared to vehicle-treated mice (Table 1). These results clearly showed that CPP treatment induces immunodeficiency in mice.

Next, we orally administered CJLP243, CJW55-10, or CJLP475 (1×10^{10} CFU per mouse) every day for two weeks starting from one day after the final injection of CPP (Fig. 3A). One day after the final administration of these probiotics, we measured immune parameters to determine whether oral uptake of these probiotics could induce an antigen-specific cell mediated immunity of immunocompromised mice (Fig. 3A). To measure immune parameters, splenocytes from each experimental mouse were rechallenged with these probiotics. Cytokine secretion levels, NK cell activity, and proliferation of immune cells were then measured. Results indicated that treatment with these probiotics enhanced the secretion of Th1-type cytokines (IFN- γ and IL-12) in immunodeficient mice than in vehicle-treated mice (Figs. 3B and C). Production levels of pro-inflammatory cytokines including IL-1 β , IL-6, IL-12, and TNF- α were augmented in these probiotics-treated mice than in vehicle-treated mice (Fig. 3C).

Furthermore, target cell killing activity of NK cells was increased in CJLP243 or CJLP475-treated mice than in vehicle-treated mice (Fig. 4A). Enhanced immune cell proliferation was observed in CJW55-10 or CJLP475-treated mice than in vehicle-treated mice (Fig. 4B). Taken together, these results indicate that consumption of selected probiotics can induce an antigen-specific cellular immune responses in immunocompromised individuals.

Finally, we compared absolute numbers of splenocytes in experimental mice to determine whether the induction of antigen-specific cellular immune responses by consumption of these probiotics could recover absolute numbers of splenocytes into normal steady status of immune homeostasis. Compared to that of CPP untreated mice (No CPP+vehicle), CPP treated mice (CPP+vehicle) exhibited significantly reduced absolute number of splenocytes (Table 2). Consumption of these probiotics in CPP treated mice increased substantial number of total splenocytes, but the numbers of splenocytes in these animals were not statistically significant compared to CPP treated mice (CPP+vehicle) (Table 2). This result might indicate that the induction




Fig. 2. BMDMs stimulated with selected probiotics up-regulates surface expression levels of co-stimulatory molecules such as CD80 and CD86. BMDMs (5×10^4 cell/well) from C57BL/6 mice were co-cultured with each heat-killed probiotics (CJW55-10, CJLP243, CJLP475) at a density of 6×10^6 CFU/mL. Three days after co-culture, flow cytometry analyses were performed to measure surface expression levels of MHC class II (A^b) (A), CD80 (B), and CD86 (C). Gray line, before stimulation; Red line, 3 d after stimulation; Vehicle, PBS treatment; LPS, LPS ($10 \mu\text{g/mL}$) treatment. All results are shown as means \pm SEM. Significant differences compared with the vehicle group are indicated as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. MFI, mean fluorescence intensity; BMDM, bone marrow derived macrophage; PBS, phosphate buffered saline; LPS, lipopolysaccharide.

Table 1. Absolute numbers of immune cells before or after treatment of cyclophosphamide (CPP)

Tissue	Population	Surface phenotype	Vehicle treatment	CPP treatment	p-value
Thymus ($\times 10^6$)	Total cell		246.67 \pm 14.70	5.83 \pm 2.03	<0.001
	DN	CD4 ⁻ CD8 ⁻	9.87 \pm 1.39	0.40 \pm 0.15	0.002
	DP	CD4 ⁺ CD8 ⁺	211.56 \pm 12.01	0.29 \pm 0.11	<0.001
	CD4 ⁺ SP	CD4 ⁺ CD8 ⁻	18.62 \pm 1.13	3.68 \pm 1.28	0.001
	CD8 ⁺ SP	CD4 ⁻ CD8 ⁺	5.99 \pm 0.54	1.41 \pm 0.47	0.003
Spleen ($\times 10^6$)	Total cell		50.17 \pm 0.73	11.00 \pm 3.12	<0.001
	T cell	CD3 ϵ^+	17.26 \pm 0.95	5.98 \pm 1.65	0.004
	CD4 ⁺ T cell	CD3 ϵ^+ CD4 ⁺	9.07 \pm 0.40	2.64 \pm 0.73	0.002
	CD8 ⁺ T cell	CD3 ϵ^+ CD8 ⁺	6.31 \pm 0.36	2.77 \pm 0.79	0.015
	B cell	B220 ⁺	25.51 \pm 0.73	2.93 \pm 0.90	<0.001
	NK cell	CD3 ϵ^- NK1.1 ⁺	1.38 \pm 0.15	0.12 \pm 0.04	0.001

All data represent the mean \pm SEM (n=3).

Significant differences were determined by p-values.

Vehicle, PBS treatment; DN, double negative cell; DP, double positive cell; SP, single positive cell; PBS, phosphate buffered saline.




Fig. 3. Oral administration of selected probiotics induces an antigen-specific cell-mediated immunity in immunodeficient mice. (A) Experimental scheme of CPP-induced immunocompromised mouse model. (B, C) After sacrificing mice, splenocytes (1×10^6 cells/well) were re-stimulated with each heat-killed probiotics (CJW55-10, CJLP243, CJLP475) at density of 6×10^6 CFU/mL for 3 d. After culture, quantities of IFN- γ (B) and pro-inflammatory cytokines (C) in culture supernatants were measured by ELISAs. No CPP+vehicle, PBS treatment without CPP administration; CPP+vehicle, PBS treatment with CPP administration; CPP+CJW55-10, CJW55-10 treatment with CPP administration; CPP+CJLP243, CJLP243 treatment with CPP administration; CPP+CJLP475, CJLP475 treatment with CPP administration. All results are shown as means \pm SEM. Significant differences compared with the “CPP+vehicle” group are indicated by ** p<0.01 and *** p<0.001. CPP, cyclophosphamide; IFN, interferon; PBS, phosphate buffered saline.




Fig. 4. Oral consumption of selected probiotics increases NK cell activity and antigen-specific leukocyte proliferation in immunodeficient mice. Experimental scheme of the CPP-induced immunocompromised mouse model is shown in Fig. 3A. (A) After sacrificing mice, splenocytes (1×10^6 cells/well) and YAC-1 cells (1×10^4 cell/well) (E:T ratio=100:1) were seeded to a 96-well plate in 200 μ L of RPMI-10 and co-incubated at 37°C for 6 h. The cytotoxicity of target cells was then measured with an LDH assay kit. (B) After sacrificing mice, splenocytes (1×10^6 cells/well) were labeled with CFSE (5 μ M) and re-stimulated with each heat-killed probiotics (CJW55-10, CJLP243, CJLP475) at density of 6×10^6 CFU/mL for 3 d. Relative proliferation of splenocytes was assessed by flow cytometry analyses. No CPP+vehicle, PBS treatment without CPP administration; CPP+vehicle, PBS treatment with CPP administration; CPP+CJW55-10, CJW55-10 treatment with CPP administration; CPP+CJLP243, CJLP243 treatment with CPP administration; CPP+CJLP475, CJLP475 treatment with CPP administration. All results are shown as means \pm SEM. Significant differences compared with the “CPP+vehicle” group are indicated by * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$. CPP, cyclophosphamide; MFI, mean fluorescence intensity; CFSE, carboxyfluorescein succinimidyl ester; PBS, phosphate buffered saline.

of antigen-specific cellular immune responses is not enough to reconstitute the steady state of immune homeostasis in immunocompromised mice.

In the present study, we evaluated an immunomodulatory effect of three different strains from *L. plantarum* in immunocompromised mice. After oral-administration of these probiotics in immunodeficient mice, we re-challenged with selected probiotics and monitored antigen-specific cellular immune responses. Combined results clearly indicated that the consumption of selected probiotics has an immunostimulatory role in immunocompromised individuals. Similar to our results, several previous observations demonstrated that the administration of certain probiotics in CPP-treated mice increased phagocytic activities of macrophages, the migration of neutrophils into periphery, and killing activities of both NK cells and cytotoxic T cells (Bujalance et al., 2007; Jang et al., 2013; Salva et al., 2014). Therefore, treatments of selected probiotics might have a potential beneficial effect in immunodeficient persons. However, it is not clear whether consumption of these probiotics enhances overall immunity against certain pathogens since our model is focused on monitoring antigen-specific immune responses in immunocompromised mice. Further study will be required to evaluate the beneficial effects of consumption of selected probiotics after challenging with specific pathogens in immunodeficient mice.

Many studies including our study supported evidence that probiotics could modulate cellular immune responses in mammals. Major components of probiotics which modulate the immune responses might be strain-specific carbohydrates or lipid components (Crump et al., 2020; Sukhithasri et al., 2013). Therefore, the interaction between certain pattern-recognition receptors and strain-specific molecular patterns might initiate the immune modulation. Indeed, several strain-specific molecular patterns from various bacterial cell walls have been identified as powerful immune modulators after interaction with several pattern recognition receptors including toll-like receptors, nucleotide-binding oligomerization domain-like receptors and C-type lectin receptors (Li and Wu, 2021). Identification of major molecular ingredients of CJW55-10,

Table 2. Absolute numbers of splenocytes among experimental mice

Group ¹⁾	Total cell number ($\times 10^7$)	p-value ²⁾
No CPP+vehicle	8.19 \pm 0.33	0.022
CPP+vehicle	5.43 \pm 0.97	
CPP+CJW55-10	6.45 \pm 0.95	0.468
CPP+CJLP243	6.13 \pm 0.89	0.607
CPP+CJLP475	7.56 \pm 1.23	0.203

All data represent the mean \pm SEM (n=6).

¹⁾ No CPP+vehicle, PBS treatment without CPP administration; CPP+vehicle, PBS treatment with CPP administration; CPP+CJW55-10, CJW55-10 treatment with CPP administration; CPP+CJLP243, CJLP243 treatment with CPP administration; CPP+CJLP475, CJLP475 treatment with CPP administration.

²⁾ Significant differences compared to that of CPP+vehicle group was determined by p-values. CPP, cyclophosphamide; PBS, phosphate buffered saline.

CJLP243 or CJLP475 which stimulate the signal transduction of specific pattern recognition molecules is useful for the development of novel immunostimulants.

Conclusion

In conclusion, we found that three probiotic strains had immune stimulatory ability in CPP-induced immunodeficient mice by macrophage activation. Thus, these probiotics might be applied to the development of ingredients for healthy functional foods.

Conflicts of Interest

Yun HS is currently employed by the CJ CheilJedang Corporation, Korea. None of the other authors had any conflict of interests.

Acknowledgements

This work was supported by the CJ CheilJedang Corporation, Korea and publication fee of this article was supported by a Korea University Grant (2022), Korea.

Author Contributions

Conceptualization: Yun HS, Chun T. Data curation: Kang SJ, Yang J. Formal analysis: Kang SJ, Yang J. Methodology: Kang SJ, Yang J, Lee NY, Lee CH, Park IB, Park SW, Lee HJ, Park HW. Software: Kang SJ. Validation: Kang SJ, Lee NY. Investigation: Chun T. Writing - original draft: Kang SJ, Lee NY. Writing - review & editing: Kang SJ, Yang J, Lee NY, Lee CH, Park IB, Park SW, Lee HJ, Park HW, Yun HS, Chun T.

Ethics Approval

A protocol of animal study was approved by the Institutional Animal Care and Use Committee (IACUC) of Korea

University (protocol numbers: KUIACUC-2020-0052).

References

- Bui VT, Tseng HC, Kozłowska A, Maung PO, Kaur K, Topchyan P, Jewett A. 2015. Augmented IFN- γ and TNF- α induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10. *Front Immunol* 6:576.
- Bujalance C, Moreno E, Jimenez-Valera M, Ruiz-Bravo A. 2007. A probiotic strain of *Lactobacillus plantarum* stimulates lymphocyte responses in immunologically intact and immunocompromised mice. *Int J Food Microbiol* 113:28-34.
- Choi DW, Jung SY, Kang J, Nam YD, Lim SI, Kim KT, Shin HS. 2018. Immune-enhancing effect of nanometric *Lactobacillus plantarum* nF1 (nLp-nF1) in a mouse model of cyclophosphamide-induced immunosuppression. *J Microbiol Biotechnol* 28:218-226.
- Crump GM, Zhou J, Mashayekh S, Grimes CL. 2020. Revisiting peptidoglycan sensing: Interactions with host immunity and beyond. *Chem Commun* 56:13313-13322.
- de Melo Pereira GV, de Oliveira Coelho B, Magalhães Júnior AI, Thomaz-Soccol V, Soccol CR. 2018. How to select a probiotic? A review and update of methods and criteria. *Biotechnol Adv* 36:2060-2076.
- Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, Hammarström L, Nonoyama S, Ochs HD, Puck JM, Roifman C, Seger R, Wedgwood J. 2007. Primary immunodeficiency diseases: An update from the international union of immunological societies primary immunodeficiency diseases classification committee. *J Allergy Clin Immunol* 120:776-794.
- Gramajo Lopez A, Gutiérrez F, Saavedra L, Hebert EM, Alvarez S, Salva S. 2021. Improvement of myelopoiesis in cyclophosphamide-immunosuppressed mice by oral administration of viable or non-viable *Lactobacillus* strains. *Front Immunol* 12:647049.
- Gutierrez-Merino J, Isla B, Combes T, Martinez-Estrada F, Maluquer De Motes C. 2020. Beneficial bacteria activate type-I interferon production via the intracellular cytosolic sensors STING and MAVS. *Gut Microbes* 11:771-788.
- Jang SE, Joh EH, Lee HY, Ahn YT, Lee JH, Huh CS, Han MJ, Kim DH. 2013. *Lactobacillus plantarum* HY7712 ameliorates cyclophosphamide-induced immunosuppression in mice. *J Microbiol Biotechnol* 23:414-421.
- Jimenez-Valera M, Moreno E, Amat MA, Ruiz-Bravo A. 2003. Modification of mitogen-driven lymphoproliferation by ceftriaxone in normal and immunocompromised mice. *Int J Antimicrob Agents* 22:607-612.
- Kambayashi T, Laufer TM. 2014. Atypical MHC class II-expressing antigen-presenting cells: Can anything replace a dendritic cell? *Nat Rev Immunol* 14:719-730.
- Lee J, Yun HS, Cho KW, Oh S, Kim SH, Chun T, Kim B, Whang KY. 2011. Evaluation of probiotic characteristics of newly isolated *Lactobacillus* spp.: Immune modulation and longevity. *Int J Food Microbiol* 148:80-86.
- Li D, Wu M. 2021. Pattern recognition receptors in health and diseases. *Signal Transduct Target Ther* 6:291.
- Mohsen S, Dickinson JA, Somayaji R. 2020. Update on the adverse effects of antimicrobial therapies in community practice. *Can Fam Physician* 66:651-659.
- Nguyen KG, Vrabel MR, Mantoosh SM, Hopkins JJ, Wagner ES, Gabaldon TA, Zaharoff DA. 2020. Localized interleukin-12 for cancer immunotherapy. *Front Immunol* 11:575597.
- Salva S, Marranzino G, Villena J, Agüero G, Alvarez S. 2014. Probiotic *Lactobacillus* strains protect against myelosuppression

- and immunosuppression in cyclophosphamide-treated mice. *Int Immunopharmacol* 22:209-221.
- Shida K, Kiyoshima-Shibata J, Nagaoka M, Watanabe K, Nanno M. 2006. Induction of interleukin-12 by *Lactobacillus* strains having a rigid cell wall resistant to intracellular digestion. *J Dairy Sci* 89:3306-3317.
- Sukhithasri V, Nisha N, Biswas L, Anil Kumar V, Biswas R. 2013. Innate immune recognition of microbial cell wall components and microbial strategies to evade such recognitions. *Microbiol Res* 168:396-406.
- Ulisse S, Gionchetti P, D'Alò S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C. 2001. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: Effects of probiotic treatment. *Am J Gastroenterol* 96:2691-2699.
- Vincenzi A, Goettert MI, Volken de Souza CF. 2021. An evaluation of the effects of probiotics on tumoral necrosis factor (TNF- α) signaling and gene expression. *Cytokine Growth Factor Rev* 57:27-38.
- Weischenfeldt J, Porse B. 2008. Bone marrow-derived macrophages (BMM): Isolation and applications. *Cold Spring Harb Protoc* 2008:pdb.prot5080.
- Won TJ, Kim B, Oh ES, Bang JS, Lee YJ, Yoo JS, Yu H, Yoon J, Hyung KE, Park SY, Hwang KW. 2011. Immunomodulatory activity of *Lactobacillus* strains isolated from fermented vegetables and infant stool. *Can J Physiol Pharmacol* 89:429-434.